SCHEMBL477015

SCHEMBL477015

Cc1nc2ccc(N3CCN(C4CCC4)CC3)nn2c1-c1ccnc(N)c1

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CSNK1E P49674 3/20 0.49
HSD17B10 Q99714 2/20 0.39
MAPK1 P28482 1/20 0.39
HRH3 Q9Y5N1 1/20 0.38
RIPK3 Q9Y572 8/20 0.38
ACVR1 Q04771 1/20 0.37
KDR P35968 1/20 0.37
TGFBR1 P36897 1/20 0.37
DYRK3 O43781 1/20 0.37
CCNT1 O60563 1/20 0.37
CDK9 P50750 1/20 0.37
DYRK1A Q13627 1/20 0.37
DYRK2 Q92630 1/20 0.37
DYRK1B Q9Y463 1/20 0.37
GAA P10253 2/20 0.37
ALOX15 P16050 1/20 0.36
HPGD P15428 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL477078 0.92 CSNK1E (0.55) CSNK1EHSD17B10HRH3RIPK3ACVR1
SCHEMBL477031 0.86 CSNK1E (0.67) CSNK1EHSD17B10MAPK1HRH3RIPK3
SCHEMBL477101 0.83 CSNK1E (0.57) CSNK1EHSD17B10HRH3RIPK3DYRK3
SCHEMBL477097 0.82 CSNK1E (0.47) CSNK1EMAPK1HRH3
SCHEMBL477052 0.79 CSNK1E (0.49) CSNK1ERIPK3KDRTGFBR1DYRK1A
SCHEMBL477051 0.79 CSNK1E (0.49) CSNK1ERIPK3KDRTGFBR1DYRK1A
SCHEMBL477117 0.78 CSNK1E (0.56) CSNK1EACVR1
SCHEMBL477096 0.78 CSNK1E (0.56) CSNK1EACVR1
SCHEMBL477095 0.78 CSNK1E (0.56) CSNK1EACVR1
SCHEMBL477000 0.78 CSNK1E (0.51) CSNK1ERIPK3KDRTGFBR1DYRK1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP claimed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US claimed
EP-2331546-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF Sanofi-aventis (FR) 2011-06-15 EP claimed
WO-2010018327-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2010-02-18 WO claimed
EP-2331546-B1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-IB]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI SA (FR) 2012-02-01 EP disclosed
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF SANOFI-AVENTIS (FR) 2011-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110312934-A1 2-ALKYL-6-CYCLOAMINO-3-(PYRIDIN-4-YL)IMIDAZO[1,2-B]-PYRIDAZINE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC APPLICATION THEREOF NR3C1, CNKSR1, NR3C2 CSNK1E 2760/4885HSD17B10 1111/4885MAPK1 3628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.